Cargando…

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers

Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parise, Carol A., Caggiano, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058253/ https://www.ncbi.nlm.nih.gov/pubmed/24955090 http://dx.doi.org/10.1155/2014/469251

Ejemplares similares

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype
por: Parise, Carol, et al.
Publicado: (2016)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
por: Lundgren, Christine, et al.
Publicado: (2019)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
por: Eldien, Marwa Mohammed Serag, et al.
Publicado: (2017)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
por: Dai, Xiaofeng, et al.
Publicado: (2014)

The influence of marital status and race/ethnicity on risk of mortality for triple negative breast cancer
por: Parise, Carol, et al.
Publicado: (2018)

Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study
por: Shokouh, Taghipour Zahir, et al.
Publicado: (2015)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000–2010
por: Parise, Carol A, et al.
Publicado: (2013)

A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana
por: Seshie, Bernard, et al.
Publicado: (2015)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor
por: Waqar, Samina, et al.
Publicado: (2018)

Subtype classification of malignant lymphoma using immunohistochemical staining pattern
por: Hashimoto, Noriaki, et al.
Publicado: (2022)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
por: Khashaba, Marwa, et al.
Publicado: (2022)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China
por: Song, Qingkun, et al.
Publicado: (2013)

Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis
por: Ma, Huiyan, et al.
Publicado: (2018)

Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification
por: Boukansa, Sara, et al.
Publicado: (2022)

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics
por: Birkman, Eva-Maria, et al.
Publicado: (2017)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status
por: Li, Qiyuan, et al.
Publicado: (2010)

Expression of ERβ, ERα and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer
por: GUO, LIYING, et al.
Publicado: (2014)

Peptidomimetic-based antibody surrogate for HER2
por: Zheng, Mengmeng, et al.
Publicado: (2021)

Investigation of colorectal cancer in accordance with consensus molecular subtype classification
por: Sawayama, Hiroshi, et al.
Publicado: (2020)

Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification
por: Kriachok, Iryna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85d2fo89jilt52va9br7h4e7v6